These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 1061995

  • 1. [The treatment of myeloproliferative syndromes].
    Maurice P.
    Schweiz Med Wochenschr; 1975 Oct 04; 105(40):1269-74. PubMed ID: 1061995
    [Abstract] [Full Text] [Related]

  • 2. Blood and neoplastic diseases. Myeloproliferative disorders.
    Lewis SM, Szur L.
    Br Med J; 1974 Nov 16; 4(5941):399-402. PubMed ID: 4425895
    [No Abstract] [Full Text] [Related]

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May 16; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 4. [Chronic myeloproliferative syndromes].
    de Ozalla CB, García Suárez J.
    Rev Clin Esp; 1999 Apr 16; 199 Suppl 1():28-36. PubMed ID: 10422448
    [No Abstract] [Full Text] [Related]

  • 5. Chronic myelocytic leukemia and the myeloproliferative diseases during the child-bearing years.
    Miller JB.
    J Reprod Med; 1976 Oct 16; 17(4):217-24. PubMed ID: 1068296
    [Abstract] [Full Text] [Related]

  • 6. The management of elderly patients with myeloproliferative disorders.
    Tura S.
    Hematol Oncol; 1993 Oct 16; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract] [Full Text] [Related]

  • 7. Myeloproliferative diseases.
    Silverstein MN.
    Postgrad Med; 1977 Feb 16; 61(2):206-10. PubMed ID: 556856
    [Abstract] [Full Text] [Related]

  • 8. [Recent progress in the treatment of hematological malignancies. IV. Therapy of myeloproliferative syndrome].
    Shibata A.
    Nihon Naika Gakkai Zasshi; 1989 Jun 16; 78(6):796-801. PubMed ID: 2794661
    [No Abstract] [Full Text] [Related]

  • 9. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T.
    Acta Haematol Pol; 1992 Jun 16; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [Abstract] [Full Text] [Related]

  • 10. [The treatment of myelo-proliferative syndromes].
    Bousser J.
    Sem Ther; 1965 Jun 16; 41(6):349-52. PubMed ID: 5234604
    [No Abstract] [Full Text] [Related]

  • 11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.
    Orv Hetil; 2006 Nov 12; 147(45):2175-9. PubMed ID: 17402211
    [Abstract] [Full Text] [Related]

  • 12. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan 12; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 13. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
    Kaufman S, Brière J, Bernard J.
    Nouv Rev Fr Hematol (1978); 1978 Apr 14; 20(1):1-15. PubMed ID: 353725
    [Abstract] [Full Text] [Related]

  • 14. Postpolycythemia myeloid metaplasia.
    Silverstein MN.
    Arch Intern Med; 1974 Jul 14; 134(1):113-7. PubMed ID: 4833938
    [No Abstract] [Full Text] [Related]

  • 15. [Efficacious treatment of a fatal blood disease: polycythemia vera].
    Sánchez Fayos J, Román Barbero A, Nevado Reviriego I.
    Sangre (Barc); 1997 Jun 14; 42(3):215-8. PubMed ID: 9381264
    [No Abstract] [Full Text] [Related]

  • 16. Essential thrombocythemia following polycythemia vera: an unusual sequence.
    Randi ML, Barbone E, Zerbinati P, Soini B, Rossi C, Girolami A.
    J Med; 1996 Jun 14; 27(5-6):363-8. PubMed ID: 9151204
    [Abstract] [Full Text] [Related]

  • 17. Treatment of myeloproliferative diseases.
    Sellei C.
    Ther Hung; 1966 Jun 14; 14(4):135-6. PubMed ID: 5228101
    [No Abstract] [Full Text] [Related]

  • 18. Essential thrombocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report.
    Murphy S, Rosenthal DS, Weinfeld A, Briere J, Faguet GB, Knospe WH, Landaw SA, Laszlo J, Pisciotta AV, Tartaglia AP.
    Cancer Treat Rep; 1982 Jul 14; 66(7):1495-500. PubMed ID: 7046930
    [Abstract] [Full Text] [Related]

  • 19. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R, Marzetta K, Miglioranza A, Redaelli S, Maino C, Maffiolini A, Gorini M.
    Recenti Prog Med; 2003 Jul 14; 94(7-8):314-20. PubMed ID: 12868237
    [Abstract] [Full Text] [Related]

  • 20. Treatment of polycythaemia vera.
    Loeb V.
    Clin Haematol; 1975 Jun 14; 4(2):441-56. PubMed ID: 1102197
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.